구조모아 (StructureMoa)항암 chemical structure spider web
방문프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Rituxan |
Overview Company | Roche / Genentech |
Overview Modality | ANTIBODY |
Overview Target | Pompe Disease |
Overview Indication | Rheumatoid Arthritis |
Overview Phase | APPROVED |
Overview Status | ACTIVE |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Established |
Overview Approval status | Approved (flag incomplete) |
Positioning Key differentiator | novel synthetic binding reagents to each of these mAbs |
Positioning Known limitation | bypassing agents |
MoA Mechanism | target cells via receptor |
MoA Biomarker | CD20 mAbs: rituximab; ofatumumab; and obinutuzumab, were screened in high |
PK/PD Species | Mouse, Rabbit |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse, Rabbit |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | thrombocytopenia (p<0 |
Clinical Safety signal | thrombocytopenia (p<0 |
Clinical Selected reported efficacy | Response 0.02258% |
Clinical Result source | ClinicalTrials.gov NCT01332994 |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT01332994 |
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Rituxan |
Overview Company | Roche / Genentech |
Overview Modality | ANTIBODY |
Overview Target | Pompe Disease |
Overview Indication | Rheumatoid Arthritis |
Overview Phase | APPROVED |
Overview Status | ACTIVE |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Established |
Overview Approval status | Approved (flag incomplete) |
Positioning Key differentiator | novel synthetic binding reagents to each of these mAbs |
Positioning Known limitation | bypassing agents |
MoA Mechanism | target cells via receptor |
MoA Biomarker | CD20 mAbs: rituximab; ofatumumab; and obinutuzumab, were screened in high |
PK/PD Species | Mouse, Rabbit |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse, Rabbit |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | thrombocytopenia (p<0 |
Clinical Safety signal | thrombocytopenia (p<0 |
Clinical Selected reported efficacy | Response 0.02258% |
Clinical Result source | ClinicalTrials.gov NCT01332994 |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT01332994 |
추천 비교
추천 비교